` KALA (Kala Pharmaceuticals Inc) vs S&P 500 Comparison - Alpha Spread

KALA
vs
S&P 500

Over the past 12 months, KALA has underperformed S&P 500, delivering a return of -16% compared to the S&P 500's +13% growth.

Stocks Performance
KALA vs S&P 500

Loading
KALA
S&P 500
Add Stock

Performance Gap
KALA vs S&P 500

Loading
KALA
S&P 500
Difference
www.alphaspread.com

Performance By Year
KALA vs S&P 500

Loading
KALA
S&P 500
Add Stock

Competitors Performance
Kala Pharmaceuticals Inc vs Peers

S&P 500
KALA
LLY
JNJ
NOVO B
ROG
Add Stock

Kala Pharmaceuticals Inc
Glance View

Market Cap
37m USD
Industry
Pharmaceuticals

Kala Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Arlington, Massachusetts and currently employs 192 full-time employees. The company went IPO on 2017-07-20. The firm's product candidate includes EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% and INVELTYS (loteprednol etabonate ophthalmic suspension) 1%. Its EYSUVIS product is a short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease. INVELTYS product is a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. The firm's AMPPLIFY technology uses selectively-sized nanoparticles that each have a coating. The firm also has a pipeline of development programs, including a clinical-stage secretome product candidate, KPI-012, initially targeting persistent corneal epithelial defects (PCED) and multiple new chemical entity (NCE) preclinical development programs targeted to address unmet medical needs.

KALA Intrinsic Value
Not Available
Back to Top